Skip to main content
Article
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys
Preventive and Behavioral Medicine Publications and Presentations
  • Dan H. Barouch, Harvard Medical School
  • Kathryn E. Stephenson, Harvard Medical School
  • Erica N. Borducchi, Harvard Medical School
  • Kaitlin Smith, Harvard Medical School
  • Kelly Stanley, Harvard Medical School
  • Anna G. McNally, Harvard Medical School
  • Jinyan Liu, Harvard Medical School
  • Peter Abbink, Harvard Medical School
  • Lori F. Maxfield, Harvard Medical School
  • Michael S. Seaman, Harvard Medical School
  • Wenjun Li, University of Massachusetts Medical School
UMMS Affiliation
Department of Medicine, Division of Preventive and Behavioral Medicine
Date
10-24-2013
Document Type
Article
Subjects
AIDS Vaccines; Animals; Antibody Formation; Female; HIV Antigens; *HIV-1; Human Immunodeficiency Virus Proteins; Immunity, Cellular; Macaca mulatta; Male; Molecular Sequence Data; Specific Pathogen-Free Organisms
Abstract
The global diversity of HIV-1 represents a critical challenge facing HIV-1 vaccine development. HIV-1 mosaic antigens are bioinformatically optimized immunogens designed for improved coverage of HIV-1 diversity. However, the protective efficacy of such global HIV-1 vaccine antigens has not previously been evaluated. Here, we demonstrate the capacity of bivalent HIV-1 mosaic antigens to protect rhesus monkeys against acquisition of infection following heterologous challenges with the difficult-to-neutralize simian-human immunodeficiency virus SHIV-SF162P3. Adenovirus/poxvirus and adenovirus/adenovirus vector-based vaccines expressing HIV-1 mosaic Env, Gag, and Pol afforded a significant reduction in the per-exposure acquisition risk following repetitive, intrarectal SHIV-SF162P3 challenges. Protection against acquisition of infection correlated with vaccine-elicited binding, neutralizing, and functional nonneutralizing antibodies, suggesting that the coordinated activity of multiple antibody functions may contribute to protection against difficult-to-neutralize viruses. These data demonstrate the protective efficacy of HIV-1 mosaic antigens and suggest a potential strategy for the development of a global HIV-1 vaccine. PAPERCLIP:
Comments

Citation: Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, Dugast AS, Alter G, Ferguson M, Li W, Earl PL, Moss B, Giorgi EE, Szinger JJ, Eller LA, Billings EA, Rao M, Tovanabutra S, Sanders-Buell E, Weijtens M, Pau MG, Schuitemaker H, Robb ML, Kim JH, Korber BT, Michael NL. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013 Oct 24;155(3):531-9. doi: 10.1016/j.cell.2013.09.061.

Full author list omitted for brevity. For the full list of authors, see article.

Related Resources
Link to Article in PubMed
PubMed ID
24243013
Citation Information
Dan H. Barouch, Kathryn E. Stephenson, Erica N. Borducchi, Kaitlin Smith, et al.. "Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys" Vol. 155 Iss. 3 (2013) ISSN: 0092-8674 (Linking)
Available at: http://works.bepress.com/wenjun_li/36/